# A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

> **NCT01445587** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Part 1; Cohort 1
- **DRUG:** Part 1; Cohort 2
- **DRUG:** Part 2; Stage 1
- **DRUG:** Part 2, Stage 2

## Key facts

- **NCT ID:** NCT01445587
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Based on the clinical activity, not safety data, of the AKT inhibitor, GSK has decided at this time to suspend further development of GSK2110183 as monotherapy.
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445587, "A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01445587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*